ZA952259B - Novel mutated viruses anti-viral compounds and novel methods of making vaccines - Google Patents

Novel mutated viruses anti-viral compounds and novel methods of making vaccines

Info

Publication number
ZA952259B
ZA952259B ZA952259A ZA952259A ZA952259B ZA 952259 B ZA952259 B ZA 952259B ZA 952259 A ZA952259 A ZA 952259A ZA 952259 A ZA952259 A ZA 952259A ZA 952259 B ZA952259 B ZA 952259B
Authority
ZA
South Africa
Prior art keywords
novel
viral compounds
mutated viruses
making vaccines
novel methods
Prior art date
Application number
ZA952259A
Other languages
English (en)
Inventor
Dennis T Brown
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of ZA952259B publication Critical patent/ZA952259B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA952259A 1994-03-21 1995-01-01 Novel mutated viruses anti-viral compounds and novel methods of making vaccines ZA952259B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/213,860 US5532154A (en) 1994-03-21 1994-03-21 Mutated alpha virus

Publications (1)

Publication Number Publication Date
ZA952259B true ZA952259B (en) 1996-09-20

Family

ID=22796796

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952259A ZA952259B (en) 1994-03-21 1995-01-01 Novel mutated viruses anti-viral compounds and novel methods of making vaccines

Country Status (14)

Country Link
US (1) US5532154A (ja)
EP (1) EP0755440A4 (ja)
JP (1) JP3821484B2 (ja)
KR (1) KR100394163B1 (ja)
CN (1) CN1122105C (ja)
AU (1) AU688887B2 (ja)
CA (1) CA2186044C (ja)
FI (1) FI963717A (ja)
IL (1) IL112990A (ja)
NZ (1) NZ283575A (ja)
RU (1) RU2194754C2 (ja)
SA (1) SA95150618B1 (ja)
WO (1) WO1995025788A1 (ja)
ZA (1) ZA952259B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP0981344A1 (en) * 1997-05-14 2000-03-01 The University of New Mexico Inhibition of cell surface protein disulfide isomerase
US7335363B2 (en) * 1997-09-18 2008-02-26 Research Development Foundation Membrane virus host range mutations and their uses as vaccine substrates
US7128915B2 (en) * 1997-09-18 2006-10-31 Research Development Foundation Membrane virus host range mutations and their uses as vaccine substrates
CA2325564A1 (en) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Inducible alphaviral gene expression system
WO2000006205A1 (en) * 1998-07-29 2000-02-10 Invitrogen Corporation Regulated expression of recombinant proteins using rna viruses
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU4366000A (en) * 1999-04-14 2000-11-14 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6890487B1 (en) 1999-09-30 2005-05-10 Science & Technology Corporation ©UNM Flow cytometry for high throughput screening
US7416903B2 (en) * 1999-09-30 2008-08-26 Stc.Unm Wavy interface mixer
US6498189B1 (en) * 1999-11-10 2002-12-24 University Of New Mexico Method for induction of L-selectin shedding
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
IES20010462A2 (en) * 2000-05-12 2001-11-14 Cyril John Higgins Use of the world wide web
AU2001275191A1 (en) * 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
NZ523831A (en) * 2000-07-13 2005-10-28 Invitrogen Corp Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP2311994A1 (en) * 2003-08-01 2011-04-20 Life Technologies Corporation Compositions and methods for preparing short RNA molecules and other nucleic acids
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
WO2010042760A2 (en) * 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
US8823943B2 (en) 2009-05-21 2014-09-02 Intellicyt Corporation System and method for separating samples in a continuous flow
US9752964B1 (en) 2009-06-22 2017-09-05 Stc.Unm Flow cytometry apparatus pulling sample stream through observation chamber
RU2720518C1 (ru) * 2018-12-18 2020-04-30 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Штамм вируса лихорадки Синдбис 1383 клон 3 (Sindbis fever virus 1383 clone 3)
KR20230022150A (ko) * 2020-03-13 2023-02-14 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. Pi4k 억제제의 항-코로나바이러스 효과 및 적용

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0500791T3 (da) * 1989-10-31 1998-04-06 Us Health Udformning og konstruktion af ikke-infektiøse human retrovirale mutanter, der mangler genomisk DNA
WO1994004185A2 (en) * 1992-08-19 1994-03-03 Trustees Of Boston University Method of inhibiting reduction of disulfide bonds

Also Published As

Publication number Publication date
EP0755440A1 (en) 1997-01-29
EP0755440A4 (en) 1998-08-19
CN1144536A (zh) 1997-03-05
WO1995025788A1 (en) 1995-09-28
KR970701778A (ko) 1997-04-12
FI963717A0 (fi) 1996-09-19
CA2186044C (en) 2005-08-23
US5532154A (en) 1996-07-02
IL112990A0 (en) 1995-06-29
FI963717A (fi) 1996-11-20
IL112990A (en) 1999-11-30
KR100394163B1 (ko) 2004-10-20
CA2186044A1 (en) 1995-09-28
AU688887B2 (en) 1998-03-19
JP3821484B2 (ja) 2006-09-13
JPH09510613A (ja) 1997-10-28
RU2194754C2 (ru) 2002-12-20
NZ283575A (en) 2001-03-30
SA95150618B1 (ar) 2006-04-22
AU2191395A (en) 1995-10-09
CN1122105C (zh) 2003-09-24

Similar Documents

Publication Publication Date Title
ZA952259B (en) Novel mutated viruses anti-viral compounds and novel methods of making vaccines
PL324906A1 (en) Vaccines against viral hepatitis of c type
CS20091A2 (en) Basic calciumaluminiumhydroxidedicarboxylate, method of its preparation and its application
IL113850A0 (en) Process and intermediates for the preparation of 3-aryluracils
GB9415369D0 (en) Mutant virus
EP0446578A3 (en) Methods for the preparation of silanes and polysilanes
IL97867A0 (en) Process for the preparation of indolones and intermediates therefor
EP0472422A3 (en) Oligohexafluoropropylene compounds and methods of making them
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
GB9005246D0 (en) New cephem compounds and processes for preparation thereof
EP0259617A3 (en) Process and preparation for inactivating viruses
GB9010359D0 (en) Enzyme and its preparation
AU678404B2 (en) Process for the purification and concentration of rubella virus
EP0440078A3 (en) Process for the preparation of retinylglycosides and intermediates for this process
ZA911652B (en) Virus free platelet derivative and method of making same
NZ295530A (en) Preparation of 1-halo-3-trialkylsilanyl-benzenes
EP0564212A3 (en) Process for the preparation of arylethylamines and substituted arylethylamines
GB9026655D0 (en) Improved hose and method of manufacture thereof
EP0456658A4 (en) Vinyloxy hydroxyalkylcycloalkane and preparation therefor
IL105369A0 (en) Process and intermediates for the preparation of 2-amino-5-methyl-pyridine
EP0564213A3 (en) Process for the preparation of arylethylamines and substituted arylethylamines
HU9400634D0 (en) Vaccine and diagnosticum against parvovirosis of gooses and barbari duks
BG98272A (en) Preparation and method for the treatment of virus hepatitis
GB8914680D0 (en) Prevention of aid virus
GB8926058D0 (en) Framing means and joints therefor